CompuGROUP stalls offer for iSoft:
This article was originally published in Clinica
CompuGROUP (Koblenz, Germany) has announced it will not increase its offer for iSoft, a move which leaves Australian firm IBA Health as the frontrunner to buy the UK medical software supplier. IBA's offer of 69p per share trumped CompuGROUP's bid of 66p per share (see Clinica No 1270, p 13).
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.